Kamada, PARI ink agreements for aerosolized drug treatments

NESS ZIONA, Israel Kamada has signed two strategic development agreements with PARI Pharma, according to published reports.

One of the agreements is for the joint clinical development of an aerosolized Alpha-1 Antitrypsin for treating cystic fibrosis and bronchiectasis, in addition to Alpha-1 Antitrypsin deficiency, which causes lung disease in adults and liver disease in adults and children. Under the agreement PARI grants Kamada an exclusive license to use its eFlow electronic nebulizer to deliver AAT in its clinical trials also for these indications.

The second agreement allows Kamada to use the eFlow nebulizer for the marketing, distribution and commercialization of the aerosolized AAT, pending a successful conclusion of the clinical trials.

“We are extremely pleased with the expansion of our collaboration with PARI, an important strategic partner,” stated David Tsur, chief executive officer of Kamada. “These agreements demonstrate a vote of confidence in Kamada. The next generation product, AAT for inhalation, holds numerous advantages over the currently used AAT for intravenous administration. Among these advantages are greater patient convenience, reduced treatment costs, larger treatment population and additional potential indications, all pending successful completion of the company’s clinical development plan.